Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation.
PMID 27519829 · European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2016 · DOI 10.1016/j.ejpb.2016.08.001
Authors: Slavomira Doktorovová; Andjelka B Kovačević; Maria L Garcia; Eliana B Souto
Abstract
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) were designed as exceptionally safe colloidal carriers for the delivery of poorly soluble drugs. SLN/NLC have the particularity of being composed of excipientsalready approved for use in medicines for human use, which offers a great advantage over any other nanoparticulate system developed from novel materials. Despite this fact, any use of excipients in new route of administration or in new dosage form requires evidence of safety. After 25 years of research on SLN and NLC, enough evidence on their preclinical safety has been published. In the present work, published data on in vitro and in vivo compatibility of SLN/NLC have been surveyed, in order to provide evidence of high biocompatibility distinguished by intended administration route. We also identified critical factors and possible weak points in SLN/NLC formulations, such as the effect of surfactants on the cell viability in vitro, which should be considered for further development.
Administration, Oral; Administration, Topical; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Colloids; Drug Carriers; Drug Delivery Systems; Excipients; Eye; Humans; Infusions, Parenteral; Inhibitory Concentration 50; Lipids; Mice; Mucous Membrane; Mutagens; Nanoparticles; Oxidative Stress; Skin; Surface Properties; Surface-Active Agents
Cite
Slavomira Doktorovová; Andjelka B Kovačević; Maria L Garcia; Eliana B Souto. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V (2016). PMID 27519829. DOI 10.1016/j.ejpb.2016.08.001.